Is CRISPR Therapeutics AG (CRSP) the Best Stock to Buy and Hold for 5 Years?

Yahoo FinanceJul 2 08:40

Guggenheim Assumes CRISPR Therapeutics at Neutral

Guggenheim analyst Debjit Chattopadhyay assumes CRISPR Therapeutics with a Neutral rating.

Analyst UpgradesJun 28 19:56

Guggenheim Initiates CRISPR Therapeutics(CRSP.US) With Hold Rating

Guggenheim analyst Debjit Chattopadhyay initiates coverage on $CRISPR Therapeutics(CRSP.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 45.2% and a total average

Futu NewsJun 28 18:31 · Ratings

Intellia Therapeutics Presents Data On Redosing With In Vivo CRISPR Therapy; 55 Mg NTLA-2001 Dose Shows 90% Median Reduction In Serum TTR At Day 28; Well Tolerated Across All Patients; Potential Redosing Advantage For Future Therapies

First-ever clinical data demonstrating redosing with an investigational in vivo CRISPR-based therapyFollow-on dosing with a 55 mg dose of NTLA-2001 led to a 90% median reduction in serum TTR at day 28

BenzingaJun 26 03:32

Here's Why We're Not At All Concerned With CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining exploration companies often lose money for years before finding success with a new tr

Simply Wall StJun 20 18:11

CRISPR Therapeutics Stock (NASDAQ:CRSP): Will It Take Off Anytime Soon?

Yahoo FinanceJun 20 02:46